Bioregulatory therapy for chronic abacterial prostatitis

Abstract

BACKGROUND: Chronic abacterial prostatitis/chronic pelvic pain syndrome (CAP/CPPS) is the most common form of chronic prostatitis.
 AIM: The aim of the study was to evaluate the effectiveness and tolerability of complex therapy in patients with CAP/CPPS using the bioregulatory peptide drug Uroprost-D.
 MATERIALS AND METHODS: The study included 47 men aged 23 to 54 years (mean 38.1 7.2 years) with CAP/CPPS (category III according to the NYHA classification, 1995). Patients of the 1st group (n = 24) were prescribed alpha-blocker tamsulosin 0.4 mg for 30 days and rectal suppositories Uroprost-D one per day for 15 days. Patients of the 2nd group (n = 23) were also prescribed tamsulosin 0.4 mg per day for 30 days and rectal suppositories indomethacin 100 mg, one per day for 15 days. The dynamics of clinical parameters was assessed on the 15, 30 and 60th day from the start of the study.
 RESULTS: By the 15th day of the study, there was a significant positive dynamics of symptoms in patients of both groups. By the 30th day of the study in patients of the 1st group the treatment effect persisted, while in patients of the 2nd group pain increased, which was expressed in an increase in the scores for the Pain domains and the total score of the NIH-CPSI questionnaire. This trend is even more pronounced by the 60th day of observation, when a significant difference was found both in the total score of the NIH-CPSI questionnaire and separately in the domains Pain, Dysuria and Quality of life. During the study, there were no statistically significant changes in the maximum urine flow rate, prostate volume and residual urine volume. Tolerability of treatment was satisfactory, the frequency of negative manifestations was slightly higher in patients of the 2nd group.
 CONCLUSIONS: The use of the bioregulatory peptide drug Uroprost-D in the complex therapy of patients with CAP was accompanied by a decrease in the severity of pain syndrome and dysuria. The appointment of Uroprost-D seems to be a pathogenetically justified alternative to the use of NSAIDs in this category of patients.